on July 19, 2004
Circulation. 2004
Published online before print July 19, 2004, doi: 10.1161/01.CIR.0000137972.74120.12
Published online before print July 19, 2004, doi: 10.1161/01.CIR.0000137972.74120.12
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 28, 2004
From Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar; Technische Universität, Munich, Germany. * To whom correspondence should be addressed. E-mail: kastrati{at}dhm.mhn.de.
Background--It is not known whether further suppression of platelet function can be achieved with clopidogrel beyond that provided by currently recommended loading and maintenance doses. We performed a comparative assessment of the antiplatelet effects of a 600-mg loading dose of clopidogrel given to patients with and without chronic clopidogrel therapy. Methods and Results--Those eligible for this prospective study were aspirin-treated patients with suspected or documented coronary artery disease admitted to hospital for coronary angiography. Two series of 20 consecutive patients each were assessed in this study. The first series included patients who had never received clopidogrel (first-use group); the second series included patients on chronic therapy with a daily dose of 75 mg clopidogrel for Conclusions--Further platelet inhibition can be achieved with clopidogrel in addition to that provided by currently recommended loading and maintenance doses. Higher doses may be warranted after assessment of their clinical efficacy and safety.
Revised on June 7, 2004
Accepted on June 10, 2004
Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy
Adnan Kastrati MD*,
1 month (chronic therapy group). Blood samples were drawn before and 6 hours after oral administration of 600 mg clopidogrel for aggregometry and flow cytometry studies. In the first-use group, loading with 600 mg clopidogrel inhibited ADP 5 µmol/L-induced platelet aggregation from 90±9% to 51±19% (P<0.001). In the chronic therapy group, loading with 600 mg clopidogrel yielded further inhibition of ADP 5 µmol/L-induced platelet aggregation in addition to that achieved by the maintenance dose of 75 mg/d, from 52±14% to 33±12% (P<0.001). In both groups, 600 mg clopidogrel loading significantly inhibited ADP-induced expression of glycoprotein IIb/IIIa and P-selectin receptors.
Key words: angina • inhibitors • platelets • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  D. O. Williams and J. D. Abbott What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax? Circulation, September 16, 2008; 118(12): 1219 - 1222. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Collet, J. Silvain, A. Landivier, M.-L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena, et al. Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study Circulation, September 16, 2008; 118(12): 1225 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart, June 1, 2008; 94(6): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. von Beckerath, D. Sibbing, and A. Kastrati A double blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days: reply Eur. Heart J., February 1, 2008; 29(3): 424 - 424. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Prabhakaran, K.R Wells, V.H. Lee, C.A. Flaherty, and D.K. Lopes Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 281 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention J. Am. Coll. Cardiol., January 15, 2008; 51(2): 172 - 209. [Full Text] [PDF]
|
|
|
|
|
|
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation, January 15, 2008; 117(2): 261 - 295. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bode and K. Huber Antiplatelet therapy in percutaneous coronary intervention Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A13 - A20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial Circulation, December 18, 2007; 116(25): 2923 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Jaumdally, C. Varma, A. D. Blann, R. J. MacFadyen, and G. Y. H. Lip Platelet Activation in Coronary Artery Disease: Intracardiac vs Peripheral Venous Levels and the Effects of Angioplasty Chest, November 1, 2007; 132(5): 1532 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Beckerath, A. Kastrati, A. Wieczorek, G. Pogatsa-Murray, D. Sibbing, I. Graf, and A. Schomig A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur. Heart J., August 1, 2007; 28(15): 1814 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Bliden, J. DiChiara, U. S. Tantry, A. K. Bassi, S. K. Chaganti, and P. A. Gurbel Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? J. Am. Coll. Cardiol., February 13, 2007; 49(6): 657 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, S. B. Shoemaker, B. Desai, H. Yuan, R. K. Charlton, E. Bernardo, M. M. Zenni, L. A. Guzman, T. A. Bass, and M. A. Costa Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation, February 13, 2007; 115(6): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Fitzgerald and A. Maree Aspirin and Clopidogrel Resistance Hematology, January 1, 2007; 2007(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, L. Nait-Saidi, J. Carvajal, A. Lehmann, M. Lambert, J.-L. Bonnet, and M.-C. Alessi Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1339 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Geisler, H. Langer, M. Wydymus, K. Gohring, C. Zurn, B. Bigalke, K. Stellos, A. E. May, and M. Gawaz Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur. Heart J., October 2, 2006; 27(20): 2420 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hamdalla and S. R. Steinhubl Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G20 - G24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Chaer, J. A. Graham, and L. Mureebe Platelet Function and Pharmacologic Inhibition Vascular and Endovascular Surgery, August 1, 2006; 40(4): 261 - 267. [Abstract] [PDF]
|
|
|
|
|
|
N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schomig, A. Kastrati, and A. Schomig Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation, November 8, 2005; 112(19): 2946 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tricoci, R. A. Harrington, M. Valgimigli, T. M. Palabrica, P. B. Burton, G. Patti, L. Lassandro Pepe, G. Di Sciascio, G. Colonna, A. Montinaro, et al. Letters Regarding Article by Patti et al, "Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study" * Response Circulation, October 25, 2005; 112(17): e282 - e283. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Moliterno and S. R. Steinhubl Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both? JAMA, September 14, 2005; 294(10): 1271 - 1273. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, B. S. Lewis, S. A. Murphy, C. H. McCabe, E. Braunwald, et al. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study JAMA, September 14, 2005; 294(10): 1224 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF]
|
|
|
|
|
|
S J Walsh, M S Spence, D Crossman, and A A J Adgey Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond Heart, September 1, 2005; 91(9): 1135 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Chaves, A. G.M.R. Sousa, J. W. Eikelboom, J. M. Rankin, A. Kastrati, J. Mehilli, H. Schuhlen, A. Dibra, J. Pache, A. Schomig, et al. Letters Regarding Article by Mehilli et al, "Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel" * Response Circulation, May 31, 2005; 111(21): e370 - e371. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gurbel, K. P. Bliden, K. M. Hayes, J. A. Yoho, W. R. Herzog, and U. S. Tantry The Relation of Dosing to Clopidogrel Responsiveness and the Incidence of High Post-Treatment Platelet Aggregation in Patients Undergoing Coronary Stenting J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1392 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L Longstreth and J. R Wertz High-Dose Clopidogrel Loading in Percutaneous Coronary Intervention Ann. Pharmacother., May 1, 2005; 39(5): 918 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Williams Clopidogrel Pretreatment for Percutaneous Coronary Intervention: Double, Double, Dose in Trouble? Circulation, April 26, 2005; 111(16): 2019 - 2021. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|